Search
Publications
Machado HE, Mitchell E, Øbro NF, Kübler K, Davies M, Leongamornlert D, Cull A, Maura F, Sanders MA, Cagan ATJ, McDonald C, Belmonte M, Shepherd MS, Vieira Braga FA, Osborne RJ, Mahbubani K, Martincorena I, Laurenti E, Green AR, Getz…
Read moreOther Useful Resources
Latest EMA publications on COVID-19 vaccines
COVID-19 Vaccine Janssen: update on safety issues
First COVID-19 vaccine approved for children aged 12 to 15 in EU
Insufficient data on use of inhaled corticosteroids to treat COVID-19
EMA issues advice on use of sotrovimab (VIR-7831) for…
EHA, AHA and GBMTA Successfully Conclude the First Joint Virtual Mini Hematology Tutorial
EHA-AHA-GBMTA Mini Hematology Tutorial
November 10-11, 2021
Meeting chairs:
Prof G Gaidano (European Hematology Association)
Prof YK Hakobyan (Armenian Hematology Association)
Dr T Kvatchadze (Georgian Association For Blood and Bone Marrow Transplantation)
EHA, the Armenian Hematology Association (AHA) and for the first time with the Georgian…
Treatment, medicine and hematology research: What patients want and doctors need (to know)
Jan Geissler, a Patient Advocate remarked about the Congress: “Over and above scientific updates, much can be achieved in partnership between hematologists and patients.
Read morePublications
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms.
Read morePublications
Dexamethasone treatment for COVID-19 is related to increased mortality in hematologic malignancy patients: results from the EPICOVIDEHA registry
Aiello TF, Salmanton-Garcia J, Marchesi F, et al. Haematologica. 2024 Aug 1;109(8):2693-2700.
Position of EHA on Personalized Medicine
The challenge
Despite its apparent complexity, personalized medicine could transform healthcare, by tailoring healthcare solutions to the individual patient, delivering ‘the right treatment to the right patient at the right time’ – and helping to get more value from healthcare spending.…
FDA Reports of Secondary Malignancies Following Chimeric Antigen Receptor (CAR) T Cell Therapies and Relative Risk: an EBMT-EHA-GoCART Coalition Statement
We need to bring your attention to the recent warning disseminated by the Food and Drug Administration (FDA) regarding T-cell lymphomas in patients undergoing Chimeric Antigen Receptor T-cell (CAR-T) therapy (1).
Read morePress Release: Better funding for research into blood diseases will save more lives
“Haematology is probably the area of medicine that has progressed the most in recent years”, said Professor Robin Foà of “La Sapienza” University of Rome.
Read more- «
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- 123
- 124
- 125
- 126
- 127
- 128
- 129
- 130
- 131
- 132
- 133
- 134
- 135
- 136
- 137
- 138
- 139
- 140
- 141
- 142
- 143
- 144
- 145
- 146
- 147
- 148
- 149
- 150
- 151
- 152
- 153
- 154
- 155
- 156
- 157
- 158
- 159
- 160
- 161
- 162
- 163
- 164
- 165
- 166
- 167
- 168
- 169
- 170
- 171
- »